DUBLIN, March 5, 2014 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/3k73qr/oral_proteins_and) has announced the addition of the "Oral Proteins and Peptides Market, 2014 - 2024" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

Owing to their complexity and instability, protein and peptide based drugs are mostly delivered by intravenous or subcutaneous routes. Based upon recent developments in R&D processes, scientists have made some progress in other routes of delivery such as transdermal, intranasal, inhalation and oral administration.

Amongst the various modes of administration, oral delivery is the most preferred route. Although very convenient, there are many challenges which hinder this route of administration. These include enzymatic and pH-dependent degradation of the amino acid based drugs in the gastrointestinal tract, low epithelial permeability and instability during formation. As a result, proteins/peptides administered orally have an extremely low (<1-2%) bioavailability.

Many large and small pharmaceutical companies have led the efforts to develop oral protein/peptides. However, there have been several setbacks. The emergence of more innovative technologies will be the key to achieving success in this field. There are a number of companies doing in-house research for developing new technologies to overcome the existing challenges. Several emerging proteins/peptides are in preclinical/discovery stage. In addition, there are a handful of molecules which are already in late stage clinical development and are likely to become commercially available in the next few years.

The 'Oral Proteins and Peptides Market, 2014-2024' report provides a comprehensive analysis of the current state of the market and the likely future evolution over the next ten years. Endogenous peptides are a smart way to utilise body's own resources to design drugs that are more specific and carry great potential to cure hard-to-treat diseases. The protein and peptide therapeutics market is a multi-billion dollar market and researchers are trying their best to improve the therapy by devising strategies for their oral delivery.

The report portrays the efforts of various pharmaceutical companies in making the transition towards oral delivery by developing innovative technologies and testing multiple drug candidates based on these technologies. A vast amount of activity is happening in this area as seen by the myriad of discoveries, patents, collaborations and grants.

Key Topics Covered:

1. Executive Summary
2. Introduction
3. Overview And Market Background
4. Drug Profiles And Market Forecast
5. Case Studies: Liprotamase, Sandimmune, Ddavp
6. Technology Platforms
7. SWOT Analysis
8. Conclusion
9. Appendix 1: Tables
10. Appendix 2: List Of Companies

Companies Mentioned:

• AIMM Therapeutics
• AbbVie
• Abbott Laboratories
• Access Pharma
• Affilogic
• Alchemia
• Almirall SA
• Alnara Pharmaceuticals
• Altus Pharmaceuticals
• Amarillo Biosciences
• Antisense Therapeutics
• Apollo Life Sciences
• Apotex
• Aptalis Pharma
• Astellas Pharma
• AstraZeneca
• Avaxia Biologics
• Barr Pharmaceuticals
• Biocon
• Biodel
• Bone Medical
• Bristol-Myers Squibb
• Cara Therapeutics
• Chiasma
• Cosmo Pharmaceuticals
• Diabetology
• Diasome Pharma
• Digestive Care
• Dr Falk Pharma GmBH
• Eli Lilly
• Emisphere
• Enteris Biopharma
• Ferring Pharmaceuticals
• Forest Laboratories
• GSK
• Generex Biotechnology
• Genta
• Giuliani
• Hemispherx Biosciences
• Hepasome
• Heptares Therapeutics
• Igy, Inc
• Inflexion
• Ipsen
• Ironwood Pharmaceuticals
• Ivax
• Janssen Pharmaceuticals
• Johnson & Johnson
• Kancer
• KeyBioScience
• Mankind Corporation
• Merck
• Merrion Pharmaceuticals
• NanoMega Medical
• NasVax
• Nektar Therapeutics
• Nobex Corporation
• Nod Pharma
• Novartis
• Novex
• Novo Nordisk
• Oramed
• Pfizer
• Pliva
• Protagonist Therapeutics
• Proxima Concepts
• QS Pharma
• Rani Therapeutics
• Rebel Pharmaceuticals
• Roche
• Sandoz
• Sanofi Aventis
• Santarus
• Schering-Plough
• Shire
• Shreya Life Sciences
• Stealth Peptides
• Synergy Pharma
• Syntaxin
• Synthetic Biologics
• TNT Pharma
• Takeda
• Tamarisk Technologies
• Tarix Pharma
• Tarsa Therapeutics
• Teva Pharmaceuticals
• Transgene Biotek Limited
• Unigene
• Upsher-Smith Laboratories
• Ventria Bioscience
• Watson Laboratories
• Zydus Cadila

For more information visit http://www.researchandmarkets.com/research/3k73qr/oral_proteins_and

Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net

SOURCE Research and Markets